Source comparison
Best Peptides for Sexual Performance: Research Comparison
PT-141 (Bremelanotide) MC4R agonist. Increases dopamine/NE in arousal centres Phase 3 RCTs, FDA-approved for female HSDD Subcutaneous injection 45–90 minutes Approved (Vyleesi) Transient nausea in 40% of users Kisspeptin-10 KISS1R agonist. Stimulates GnRH and
This comparison does not assign a generated winner or score.
- PT-141 (Bremelanotide)
- MC4R agonist. Increases dopamine/NE in arousal centres
- Phase 3 RCTs, FDA-approved for female HSDD
- Subcutaneous injection
- 45–90 minutes
- Approved (Vyleesi)
- Transient nausea in 40% of users
- Kisspeptin-10
- KISS1R agonist. Stimulates GnRH and LH/testosterone
- Phase 2 RCT in men with HSDD
- IV infusion (trial); subQ not validated
- 60–120 minutes
- Not approved
- IV administration impractical; subQ efficacy unproven
- Melanotan-II
- Non-selective melanocortin agonist
- Phase 1 trials only; never progressed
- 30–60 minutes
- Not approved; FDA warnings issued
- Off-target MC1R activation causes tanning; unknown long-term safety
- GHRP-6 / Ipamorelin
- GH secretagogue. Raises GH and IGF-1
- No trials for sexual function endpoints
- Subcutaneous or IV
- Variable (GH peaks at 30 min)
- Not approved for this use
- Theoretical mechanism; no human efficacy data for libido or arousal